VOLUNTARY ANNOUNCEMENT OBTAINMENT OF THE DRUG SUPPLEMENTARY APPLICATION APPROVAL NOTICE FOR LEUPRORELIN ACETATE MICROSPHERES FOR INJECTION 11.25MG (THREE-MONTH FORMULATION)
(1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 24 SEPTEMBER 2026; AND (2) THE 2026 SPECIAL INTERIM DIVIDEND TO REWARD SHAREHOLDERS